Abbott Buys Remaining Stake In Mavik And Tarka From Aventis For $300 Mil.
This article was originally published in The Pink Sheet Daily
Executive Summary
Abbott originally obtained marketing rights for the two cardiovascular drugs under a 1991 licensing agreement. Abbott expects peak sales to reach $700 mil. (versus $200 mil.-plus in 2003). The sale is not related to the Sanofi merger, Aventis says, but rather is part of an effort to divest underperforming brands.
You may also be interested in...
Wellbutrin XL Paragraph IV Filing
The first ANDA with a Paragraph IV certification for GlaxoSmithKline's Wellbutrin XL was filed Sept. 21, according to FDA's Nov. 17 update of Paragraph IV filings
Wellbutrin XL Paragraph IV Filing
The first ANDA with a Paragraph IV certification for GlaxoSmithKline's Wellbutrin XL was filed Sept. 21, according to FDA's Nov. 17 update of Paragraph IV filings
Abbott Flomax Reps Will Shift To Smaller Products Once Co-Promotion Deal Ends
The company will move from actively co-promoting to merely distributing Flomax at the end of August under its 1999 agreement with Boehringer Ingelheim. Tarka and Omnicef could pick up reps from the Flomax sales force, Abbott says.